Publication number US20130323198 A1 Publication type Application Application number US 13/906,231 Publication date Dec 5, 2013 Filing date May 30, 2013 Priority date May 31, 2012
"The invention also includes use of any other pre-clinical HDAC inhibitors, including without limitation, Kevetrin, an agent selective for HDAC2, that are later determined to be useful for the treatment of cancer via the reduction or inhibition of histone deacetylase activity in combination with AMG 900"